clinical trial · NCT05676931
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
Gilead Sciences·phase2·active not recruiting·n = 400
Advanced Non-Small Cell Lung CancerDomvanalimabQuemliclustatZimberelimabDocetaxelPlatinum-Based Doublet
brief summary
The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tolerability of immunotherapy-based combination therapy.
started
Feb 21, 2023
primary completion
Dec 1, 2027
completion
Dec 1, 2027
last updated
Oct 2, 2025
detailed description
The study includes multiple substudy arms (Substudy A, B, C), which will evaluate immunotherapy-based combinations.
official title
A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol